Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pumosetrag
- Development stage
- Phase 3
- Lead developer
- Dynogen Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Pumosetrag is an orally available small molecule drug developed as a selective partial agonist of the serotonin 5-HT3 receptor. It was investigated primarily for the treatment of irritable bowel syndrome with constipation (IBS-C) and gastroesophageal reflux disease (GERD), including nocturnal GERD. Pumosetrag acts as a prokinetic agent by modulating gastrointestinal motility—delaying liquid gastric emptying through proximal stomach relaxation and enhancing fasting antroduodenal migrating motor complex activity, while also speeding up small intestinal transit. Its mechanism is mediated by partial agonism at the 5-HT3 receptor, with species-specific differences in efficacy observed in preclinical studies. Clinical trials reached up to phase III for IBS and phase II for GERD; however, development has been discontinued[2][3][4][6].
- Other names
- pumosetrag hydrochloride
02
Targets
5-HT (Serotonin receptors)
Beyond the preview
Go deeper on pumosetrag.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pumosetrag.